New hope for kids with stubborn kawasaki disease: drug targets fever and heart risks
NCT ID NCT01596335
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a drug called TA-650 in 31 children with Kawasaki disease whose fever did not go away after standard IVIG treatment. The goal was to see if TA-650 could bring down the fever faster and prevent damage to heart arteries compared to another immunoglobulin treatment. The drug was given as a single IV infusion, and researchers also checked how the body processes it.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TA-650 (a drug given by IV infusion)
- What this could lead to
- If it works, this could offer a new treatment option for children with Kawasaki disease who don't respond to standard therapy, potentially reducing fever and preventing heart complications.
- What could go wrong
- This is a small, completed phase 3 trial with only 31 participants, so results may not apply to all patients. The drug may not be more effective than the control treatment, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KAWASAKI DISEASE REFRACTORY TO INITIAL THERAPY WITH INTRAVENOUS IMMUNOGLOBULIN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Investigational site
Chugoku, Japan
-
Investigational site
Chūbu, Japan
-
Investigational site
Hokkaido, Japan
-
Investigational site
Kanto, Japan
-
Investigational site
Kyushu, Japan
-
Investigational site
Shinetu, Japan
-
Investigational site
Tōhoku, Japan
-
Investigational site
Tōkai, Japan